Business Description
Ayala Pharmaceuticals Inc
NAICS : 325412
SIC : 2833
ISIN : US0076244062
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.59 | |||||
Equity-to-Asset | -1.47 | |||||
Debt-to-Equity | -0.34 | |||||
Debt-to-EBITDA | -0.34 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -24.79 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -81.4 | |||||
3-Year EBITDA Growth Rate | -30.4 | |||||
3-Year EPS without NRI Growth Rate | -42.8 | |||||
3-Year FCF Growth Rate | -25 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.62 | |||||
9-Day RSI | 8.34 | |||||
14-Day RSI | 20.91 | |||||
6-1 Month Momentum % | -82.09 | |||||
12-1 Month Momentum % | -88.86 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.3 | |||||
Quick Ratio | 0.3 | |||||
Cash Ratio | 0.2 | |||||
Days Sales Outstanding | 8007.19 | |||||
Days Payable | 208061.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.3 | |||||
Shareholder Yield % | -429.54 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -282075 | |||||
Net Margin % | -469137.5 | |||||
FCF Margin % | -164312.5 | |||||
ROA % | -372.58 | |||||
ROIC % | -301.08 | |||||
3-Year ROIIC % | -33.1 | |||||
ROC (Joel Greenblatt) % | -1295.65 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Revenue | 485.63 | |||||
EV-to-FCF | -0.3 | |||||
Earnings Yield (Greenblatt) % | -588.24 | |||||
FCF Yield % | -1668.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ayala Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.008 | ||
EPS (TTM) (€) | -5.022 | ||
Beta | 0 | ||
Volatility % | 100.91 | ||
14-Day RSI | 20.91 | ||
14-Day ATR (€) | 0.010408 | ||
20-Day SMA (€) | 0.08265 | ||
12-1 Month Momentum % | -88.86 | ||
52-Week Range (€) | 0.01 - 1.26 | ||
Shares Outstanding (Mil) | 42.59 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ayala Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ayala Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ayala Pharmaceuticals Inc Frequently Asked Questions
What is Ayala Pharmaceuticals Inc(STU:FAD)'s stock price today?
When is next earnings date of Ayala Pharmaceuticals Inc(STU:FAD)?
Does Ayala Pharmaceuticals Inc(STU:FAD) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |